Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Corti

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Poupak Fallahi, et al.
Molecular and Cellular Endocrinology|June 17, 2014
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Poupak Fallahi, et al.
Molecular and Cellular Endocrinology|June 17, 2014
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Pageof 7